Prostate Cancer
Show Only Open Trials
1.
CALGB 70807: The Men's Eating and Living (MEAL) Study: A Randomized Trial of Diet to Alter Disease Progression in Prostate Cancer Patients on Active Surveillance
- Study Status: Open to Enrollment
- Sponsor: CALGB
2.
A Phase 1b Safety Study of Abiraterone Acetate (JNJ 212082) and Docetaxel in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) (COU-AA-206)
- Study Status: Open to Enrollment
- Sponsor: Cougar Biotechnology
- Disease Status and/or Stage: Metastatic Castration-Resistant Prostate Cancer
3.
A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer
- Study Status: Open to Enrollment
- Sponsor: Cancer and Leukemia Group B, National Cancer Institute
- Disease Status and/or Stage: High Risk, Clinically Localized Prostate Cancer
4.
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects with Castration Resistant Prostate Cancer That Have Received Prior Treatment with Docetaxel
- Study Status: Open to Enrollment
- Sponsor: Bristol-Myers Squibb
- Disease Status and/or Stage: Castration-Resistant Prostate Cancer
5.
Radioimmunotherapy Phase I Dose-Escalation Studies in Prostate Cancer using 177Lu-J591 Antibody: Dose Fractionation Regimen
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Metastatic Prostate Cancer
6.
A Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients with Metastatic Androgen-Independent Prostate Cancer
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Metastatic, Hormone-Refractory Prostate Cancer
7.
A Randomized Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and ketoconazole in Patients with High-Risk Castrate Biochemically Relapsed Prostate Cancer After Local Therapy
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Relapsed Prostate Cancer
8.
A Phase I Trial of Docetaxel/Prednisone plus Fractionated 177Lu-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients with Metastatic, Castrate-Resistant Prostate Cancer
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Metastatic Prostate Cancer
9.
A Phase III trial of short term androgen deprivation with pelvic lymph node or prostate bed only radiotherapy (SPPORT) in prostate cancer patients with a rising PSA after radical prostatectomy
- Study Status: Open to Enrollment
- Sponsor: Radiation Therapy Oncology Group, National Cancer Institute
- Disease Status and/or Stage: Prostate Cancer After Radical Prostatectomy
10.
A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell Carcinoma
- Study Status: Open to Enrollment
- Sponsor: Cancer and Leukemia Group B (CALGB); National Cancer Institute (NCI)
- Disease Status and/or Stage: Advanced Transitional Cell Carcinoma
11.
A Phase I/II, Open-Label, Dose Escalation Study of CDX-1401 in Patients with Malignances Known to Express NY-ESO-1
- Study Status: Closed to Enrollment
- Sponsor: Celldex Therapeutics
- Disease Status and/or Stage: Progressive Disease after therapies with curative potential or approved salvage regimen
12.
Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism (VTE) in Patients with Cancer
- Study Status: Closed to Enrollment
- Disease Status and/or Stage: Any Stage of Cancer
